How to take the pharmacy IPO road

"Inquiries" list, the industry insiders were astonished. Analysts stated that there are two possibilities for the suspension of review at Yifeng Medical Pharmacy. One is that the issuer actively requests suspension and the other is that the audit cannot be carried out normally due to other reasons. According to the information learned by the newspaper from Yifeng Pharmacy, the suspension of the review was due to the replacement of its attorneys and the re-submission of the materials needed to be renamed, which will not affect their planned plan for the recent release of the prospectus.

The issue of shares by companies and their successful listing (ie, IPOs) are regarded by all Chinese companies as a top priority for development. In order to obtain an approval letter for issuing IPOs, innumerable enterprises will be able to do their best. The same is true of drug retailers.

Compared with other industries, the chain pharmacy industry can be said to be a loser in the Chinese capital market. As of the end of 2012, there were 2472 listed companies in Shanghai and Shenzhen, and among such large listed companies, there was no chain pharmacy solely based on pharmaceutical retailing. Only Jiashitang, Jiuzhoutong, and Nanjing Several companies, such as pharmaceuticals, Tong Ren Tang and Fosun Pharma, have certain links with the pharmaceutical retail industry.

The recently accelerated IPO pre-disclosure process is expected to change this situation. Yunnan Hongxiang Hall of Fame has issued the prospectus as early as May of last year and passed the review meeting. Its sponsoring organization has submitted the issuance plan within the time limit set before May 7 of this year. The IPO is just around the corner and is only waiting to issue approvals; April 29 In the evening, people’s pharmacies appeared in the eighth batch of 12 IPO pre-disclosed lists of the China Securities Regulatory Commission, and disclosed the prospectus, and the IPO process was officially launched. Not surprisingly, chain pharmacies will soon appear in China's securities market.

Under the current situation of the approval system, the Chinese enterprises want to successfully access the capital market, such as the Tang and Mentoring of Shi Tian, ​​and the process is arduous and full of uncertainty. Yifeng is the same, and the same is true for IPO. Although it is difficult, the issue of listing to the company still outweighs the disadvantages, and it is even more so for chain pharmacies that are in urgent need of financial support. First, the IPO has solved the financial problems that constrain the future development of the company, allowing chain pharmacies to speed up new stores, accelerate expansion, and launch Information management systems have been funded; secondly, they are urged to help companies establish and improve modern enterprise systems and improve the standardization and high efficiency of their operations; thirdly, media and networks continue to pay attention to and report on listed companies. The free publicity and promotion of enterprises can help increase the visibility of the company. Fourth, the more important thing is that through the IPO, enterprises can open up the channels for access to the capital market, so that they can finance at a lower cost in the future, and large shareholders and social investment. Persons, institutions, etc. are also indispensable and important resources for enterprise development.

How to take the road of the chain pharmacy IPO? For many chain pharmacies, the 600 listed companies that have submitted applications for issuance are undoubtedly the “barrier lakes” in front of them. According to the progress of the current review and listing, it takes almost two to three years. There are four options for chain drugstores that are interested in listing: One is to meet difficulties and continue to apply for IPO. This applies to those chain pharmacies that have standardized operation, obvious competitiveness, good efficiency, and outstanding profit model. The second is to find another way, like Jiuzhou Pharmacy, listed overseas; the third is indirect listing through restructuring, mergers, acquisitions, asset injections, etc.; The fourth is a mind to rely on their own strength development. The author's suggestion is: If the company is relatively strong, has a certain reputation and core competitiveness, or is listed in the domestic IPO as well.